Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (261-270 of 277) with videos related to

Pageof 28
Sort By:
JCO Precision Oncology|February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1HMohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced CancersTakeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid TumorsBlessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Oncogene|November 16, 2021
Correction to: Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Cell|May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsBryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.
Pageof 28

Showing results (261-270 of 277) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1HMohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced CancersTakeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid TumorsBlessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Oncogene|November 16, 2021
Correction to: Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Cell|May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsBryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.
Pageof 28